Brief: Bioatla Granted FDA Fast Track Designation For Ozuriftamab Vedotin

Bioatla

23/07/2024 13:29

July 23 (Reuters) - Bioatla Inc  BCAB.O :
    * BIOATLA GRANTED FDA FAST TRACK DESIGNATION FOR OZURIFTAMAB
VEDOTIN (CAB-ROR2-ADC) FOR TREATMENT OF PATIENTS WITH RECURRENT
OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK
    * BIOATLA INC: ON TRACK TO MEET WITH FDA FOR GUIDANCE ON A
POTENTIALLY REGISTRATIONAL TRIAL IN 2H 2024

Source text for Eikon:  ID:nGNX1b72x1 
Further company coverage:  BCAB.O 

 ((Reuters.Briefs@thomsonreuters.com;))